Streetbeat News

Regulatory

SPY

S&P predicts that the U.S. Federal Reserve will maintain its current monetary policy in the upcoming rate-setting meeting, despite inflation being significantly above target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:38 pm

ZIVO

ZIVO Bioscience, Inc. (NASDAQ:ZIVO) has initiated a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The product is designed to boost immune response, allowing birds to combat the disease without the use of antimicrobial compounds. The study aims to confirm the positive effects of ZIVO's non-antibiotic alternative, including reduced mortality and reduction in the incidence and severity of intestinal lesions. The results are expected by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:35 pm

QTNTQ

AliveDx has received three IVDR CE Marks for its MosaiQ solution, a multiplexed autoimmune diagnostics solution. The marks were awarded for the MosaiQ Centromere Protein B (CENP-B) microarray, the MosaiQ AiPlex CTD multiplexed microarray immunoassays, and the MosaiQ AiPlex CTD Quality Controls. The company plans to launch its autoimmune testing portfolio in the European Union and other CE Mark recognizing geographies, aiming to provide improved workflow and faster diagnosis and treatment of patients with autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:29 pm

BYSI

BeyondSpring Inc. (NASDAQ:BYSI) has regained compliance with the Nasdaq minimum bid price requirement. The company received a notification from the Nasdaq Stock Market LLC that for 10 consecutive business days, from October 13, 2023 to October 26, 2023, the closing bid price of the company's ordinary shares has been at $1.00 per share or greater.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:25 pm

ASLE

AerSale Corporation (NASDAQ:ASLE) has achieved a 50% visual advantage in low visibility operations for its AerAware Enhanced Flight Vision System (EFVS) on the Boeing B737NG aircraft. This breakthrough was achieved through a collaboration with Universal Avionics and Elbit Systems. The EFVS improves pilot situational awareness, reduces the risk of accidents, and allows for more efficient operations. Final approval by the U.S. Federal Aviation Administration (FAA) of the AerAware STC for the Boeing B737NG is pending.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:20 pm

BLUE

Bluebird Bio has agreed to sell a potential Rare Pediatric Disease Priority Review Voucher (PRV) for $103 million, contingent on FDA approval of the biologics license application for Lovotibeglogene Autotemcel (Lovo-cel) for Sickle Cell Disease.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:19 pm

CTMX

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced that it will present preclinical data for its conditionally activated cytokine program, CX-801, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The company anticipates filing an IND for CX-801 by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:15 pm

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) has gained alignment with the FDA on a plan to lift the clinical hold on the Phase 1/2 INGLAXA clinical trial for 4D-310 for Fabry disease cardiomyopathy. The company has initiated a single non-human primate safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus immunosuppressive regimen. The INGLAXA protocol has been amended to minimize the risk of atypical hemolytic uremic syndrome associated with intravenous AAV dosing. Interim clinical data from INGLAXA is expected to be presented in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:13 pm

AMTX

Aemetis, Inc. (NASDAQ:AMTX) has been selected by India's three government-controlled oil marketing companies (OMCs) to supply an estimated $150 million of biodiesel under cost-plus purchase contracts for approximately 40 million gallons of biodiesel during the one year period starting October 2023. This comes as part of India's National Policy on Biofuels which targets a 5% minimum blend on direct sale of biodiesel by 2030. Aemetis plans to continue to expand capacity to meet growing demand under the OMC cost-plus contract structure.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:12 pm

PHAT

The FDA has approved Phathom Pharmaceuticals' reformulated Vonoprazan tablets for Voquezna Triple Pak and Voquezna Dual Pak for H. Pylori infection in adults. This approval could potentially increase the company's market share and revenues.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:11 pm